Researchers Down Under are keeping a close eye on groundbreaking advancements in cancer treatment originating from Portugal, where a novel approach using carbon nanocapsules is set to revolutionise radiotherapy. The CarboNCT project, spearheaded by the University of Aveiro, is exploring an exciting alternative to the established Neutron Capture Therapy (NCT) by investigating the use of lithium-6. This departure from the traditional boron-10 element aims to significantly enhance the effectiveness of radiotherapy while dramatically minimising collateral damage to healthy tissues surrounding cancerous growths.
The core principle of NCT involves delivering a specific element directly into cancer cells. Once in place, these elements are then bombarded with neutrons, triggering a nuclear reaction. This reaction releases a potent burst of energy, precisely targeted to obliterate the cancer cells. What makes this method particularly remarkable is the extremely short range of this energy release, effectively confining its destructive power to the cellular level, a single cell at a time.
A New Frontier: Lithium-6 in Nanocapsules
While boron-10 has been the cornerstone of this therapeutic strategy, the team at the University of Aveiro is pushing the boundaries by examining the potential of lithium-6. Their hypothesis is that lithium-6 could offer superior therapeutic efficiency and a heightened level of treatment precision. This could translate to more effective tumour eradication and a better quality of life for patients undergoing treatment.
Gil Gonçalves, a leading researcher in the university’s Department of Mechanical Engineering and the project’s chief coordinator, highlighted the “multifunctional” nature of these innovative nanocapsules. These microscopic marvels are engineered not only to transport high concentrations of active isotopes but also to bolster the overall safety and efficacy of the therapy.
One of the persistent hurdles in this type of therapy is the critical need to ensure that the active therapeutic agent reaches the tumour cells in adequate amounts. These sophisticated carbon nanocapsules are designed to overcome this challenge by increasing the stability of the compound and facilitating a more controlled and targeted delivery mechanism. This precise delivery is crucial in reducing the likelihood of unintended toxic effects on healthy cells.
Promising Early Results and Future Potential
“The results we have obtained thus far are exceptionally promising,” stated Gonçalves. “The nanocapsules have demonstrated remarkable biocompatibility when tested on non-cancerous cells, and crucially, they have exhibited an effective capacity for accumulation within tumour cells.” This dual action of being safe for healthy cells while concentrating in cancerous ones is a significant step forward.
Furthermore, a unique characteristic of these nanoparticles is their natural fluorescence. This inherent property means that their presence within cells can be readily monitored. This opens up exciting possibilities for real-time tracking of the nanocapsules, potentially evolving into an invaluable tool for monitoring the progress and effectiveness of cancer treatments.
Collaboration and the Road to Clinical Application
The development of this cutting-edge project is a collaborative effort, involving the Faculty of Medicine at the University of Coimbra and the University of Pavia, working within the Laboratory of Applied Nuclear Energy (LENA). Such interdisciplinary cooperation is often the catalyst for significant scientific breakthroughs.
The University has expressed optimism that if ongoing research continues to validate the potential demonstrated in these early stages, this novel approach could pave the way for clinical applications. This could ultimately lead to the development of an entirely new generation of drugs and treatment protocols for neutron therapy, offering new hope to cancer patients.
Cancer remains one of the most formidable health challenges globally, claiming countless lives and posing a significant burden on modern medicine. In Portugal, the outlook for new cancer diagnoses is concerning, with projections indicating an approximate 20 per cent increase by 2040. This figure is slightly higher than the European Union’s estimate of an 18 per cent rise. To illustrate the scale of the problem, the Portuguese Oncology Institute (IPO) in Porto alone diagnoses around 10,000 new cancer cases each year. Innovations like the CarboNCT project offer a beacon of hope in the ongoing fight against this pervasive disease.
